Brokers Set Expectations for CollPlant Biotechnologies Ltd.’s Q1 2025 Earnings (NASDAQ:CLGN)
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN – Free Report) – HC Wainwright issued their Q1 2025 earnings per share estimates for CollPlant Biotechnologies in a note issued to investors on Friday, April 5th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.36) for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for CollPlant Biotechnologies’ current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for CollPlant Biotechnologies’ Q2 2025 earnings at $0.31 EPS, Q3 2025 earnings at ($0.32) EPS and Q4 2025 earnings at ($0.30) EPS.
CollPlant Biotechnologies Trading Down 3.0 %
Shares of CLGN opened at $5.10 on Monday. CollPlant Biotechnologies has a 1 year low of $4.22 and a 1 year high of $8.90. The stock has a market cap of $58.40 million, a P/E ratio of -7.97 and a beta of 0.24. The stock’s 50-day moving average price is $5.32 and its two-hundred day moving average price is $5.46.
Hedge Funds Weigh In On CollPlant Biotechnologies
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its holdings in CollPlant Biotechnologies by 53.9% during the first quarter. Bank of America Corp DE now owns 7,389 shares of the company’s stock worth $52,000 after buying an additional 2,589 shares during the last quarter. UBS Group AG boosted its holdings in CollPlant Biotechnologies by 119.1% during the second quarter. UBS Group AG now owns 7,514 shares of the company’s stock worth $60,000 after buying an additional 4,085 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its holdings in CollPlant Biotechnologies by 11.3% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 50,150 shares of the company’s stock worth $320,000 after buying an additional 5,100 shares during the last quarter. Credit Suisse AG acquired a new stake in shares of CollPlant Biotechnologies during the fourth quarter worth about $51,000. Finally, Villere ST Denis J & Co. LLC raised its position in shares of CollPlant Biotechnologies by 2.5% during the third quarter. Villere ST Denis J & Co. LLC now owns 300,173 shares of the company’s stock worth $1,672,000 after purchasing an additional 7,450 shares during the period. Institutional investors own 21.69% of the company’s stock.
About CollPlant Biotechnologies
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CollPlant Biotechnologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and CollPlant Biotechnologies wasn’t on the list.
While CollPlant Biotechnologies currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
MarketBeat’s analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
